Cargando…

Exometabolom analysis of breast cancer cell lines: Metabolic signature

Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Lucas, Erbes, Thalia, Halbach, Sebastian, Brummer, Tilman, Jäger, Markus, Hirschfeld, Marc, Fehm, Tanja, Neubauer, Hans, Stickeler, Elmar, Kammerer, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544000/
https://www.ncbi.nlm.nih.gov/pubmed/26293811
http://dx.doi.org/10.1038/srep13374
_version_ 1782386634245799936
author Willmann, Lucas
Erbes, Thalia
Halbach, Sebastian
Brummer, Tilman
Jäger, Markus
Hirschfeld, Marc
Fehm, Tanja
Neubauer, Hans
Stickeler, Elmar
Kammerer, Bernd
author_facet Willmann, Lucas
Erbes, Thalia
Halbach, Sebastian
Brummer, Tilman
Jäger, Markus
Hirschfeld, Marc
Fehm, Tanja
Neubauer, Hans
Stickeler, Elmar
Kammerer, Bernd
author_sort Willmann, Lucas
collection PubMed
description Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification of cell culture supernatants was performed by cis-diol specific affinity chromatography using boronate-derivatized polyacrylamide gel. Samples were analyzed by application of reversed phase chromatography coupled to a triple quadrupole mass spectrometer. Collectively, we determined 23 compounds from RNA metabolism, two from purine metabolism, five from polyamine/methionine cycle, one from histidine metabolism and two from nicotinate and nicotinamide metabolism. We observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. Differences in metabolite excretion resulting from cancerous metabolism can be integrated into altered processes on the cellular level. Modified nucleosides have great potential as biomarkers in due consideration of the heterogeneity of breast cancer that is reflected by the different molecular subtypes of breast cancer. Our data suggests that the metabolic signature of breast cancer cell lines might be a more subtype-specific tool to predict breast cancer, rather than a universal approach.
format Online
Article
Text
id pubmed-4544000
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45440002015-09-01 Exometabolom analysis of breast cancer cell lines: Metabolic signature Willmann, Lucas Erbes, Thalia Halbach, Sebastian Brummer, Tilman Jäger, Markus Hirschfeld, Marc Fehm, Tanja Neubauer, Hans Stickeler, Elmar Kammerer, Bernd Sci Rep Article Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification of cell culture supernatants was performed by cis-diol specific affinity chromatography using boronate-derivatized polyacrylamide gel. Samples were analyzed by application of reversed phase chromatography coupled to a triple quadrupole mass spectrometer. Collectively, we determined 23 compounds from RNA metabolism, two from purine metabolism, five from polyamine/methionine cycle, one from histidine metabolism and two from nicotinate and nicotinamide metabolism. We observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. Differences in metabolite excretion resulting from cancerous metabolism can be integrated into altered processes on the cellular level. Modified nucleosides have great potential as biomarkers in due consideration of the heterogeneity of breast cancer that is reflected by the different molecular subtypes of breast cancer. Our data suggests that the metabolic signature of breast cancer cell lines might be a more subtype-specific tool to predict breast cancer, rather than a universal approach. Nature Publishing Group 2015-08-21 /pmc/articles/PMC4544000/ /pubmed/26293811 http://dx.doi.org/10.1038/srep13374 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Willmann, Lucas
Erbes, Thalia
Halbach, Sebastian
Brummer, Tilman
Jäger, Markus
Hirschfeld, Marc
Fehm, Tanja
Neubauer, Hans
Stickeler, Elmar
Kammerer, Bernd
Exometabolom analysis of breast cancer cell lines: Metabolic signature
title Exometabolom analysis of breast cancer cell lines: Metabolic signature
title_full Exometabolom analysis of breast cancer cell lines: Metabolic signature
title_fullStr Exometabolom analysis of breast cancer cell lines: Metabolic signature
title_full_unstemmed Exometabolom analysis of breast cancer cell lines: Metabolic signature
title_short Exometabolom analysis of breast cancer cell lines: Metabolic signature
title_sort exometabolom analysis of breast cancer cell lines: metabolic signature
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544000/
https://www.ncbi.nlm.nih.gov/pubmed/26293811
http://dx.doi.org/10.1038/srep13374
work_keys_str_mv AT willmannlucas exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT erbesthalia exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT halbachsebastian exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT brummertilman exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT jagermarkus exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT hirschfeldmarc exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT fehmtanja exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT neubauerhans exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT stickelerelmar exometabolomanalysisofbreastcancercelllinesmetabolicsignature
AT kammererbernd exometabolomanalysisofbreastcancercelllinesmetabolicsignature